- Home
- ACRS vs PBAM Comparison
ACRS vs PBAM Comparison
Compare ACRS & PBAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | PBAM |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 492.4M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ACRS | PBAM |
|---|---|---|
| Price | $3.97 | $85.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $10.09 | ★ $99.75 |
| AVG Volume (30 Days) | ★ 3.9M | 99.1K |
| Earning Date | 11-13-2026 | 01-15-2027 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ 4.34 |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | $12.32 |
| Revenue Next Year | N/A | $7.69 |
| P/E Ratio | ★ N/A | $19.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $81.85 |
| 52 Week High | $6.60 | $92.09 |
Technical Indicators
Market Signals| Indicator | ACRS | PBAM |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 46.35 |
| Support Level | $3.18 | $83.95 |
| Resistance Level | $4.67 | $88.00 |
| Average True Range (ATR) | 0.25 | 1.72 |
| MACD | 0.11 | 0.13 |
| Stochastic Oscillator | 86.34 | 61.39 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About PBAM Private Bancorp of America Inc. Common Stock
Private Bancorp of America Inc is a commercial bank chartered by the State of California. It provides comprehensive banking services, including deposit accounts, treasury management services, and lending solutions tailored to high-net-worth individuals, professionals, family offices, closely-held businesses, real estate entrepreneurs, and small to mid-sized businesses. Lending activities include commercial real estate loans, commercial and industrial loans, and government-guaranteed lending programs.